18-Fluoro-deoxyglucose positron emission tomography report interpretation as predictor of outcome in diffuse large B-cell lymphoma including analysis of ‘indeterminate’ reports

References

• Jemal A, Siegel R, Ward E, et al Cancer statistics, 2008. CA Cancer J Clin 2008;58:71–96.
   PubMed Web of Science ®Google Scholar
• Morton LM, Wang SS, Devesa SS, Hartge P, Weisenburger DD, Linet MS. Lymphoma incidence patterns by WHO subtype in the United States, 1992–2001. Blood 2006;107:265–276.
   PubMed Web of Science ®Google Scholar
• Seyfarth B, Josting A, Dreyling M, Schmitz N. Relapse in common lymphoma subtypes: salvage treatment options for follicular lymphoma, diffuse large cell lymphoma and Hodgkin disease. Br J Haematol 2006;133:3–18.
   PubMed Web of Science ®Google Scholar
• Bangerter M, Kotzerke J, Griesshammer M, Elsner K, Reske SN, Bergmann L. Positron emission tomography with 18-fluorodeoxyglucose in the staging and follow-up of lymphoma in the chest. Acta Oncol 1999;38:799–804.
   PubMed Web of Science ®Google Scholar
• Bangerter M, Moog F, Griesshammer M, Elsner K, Kotzerke J, Heimpel H. Role for whole body FDG-PET imaging in predicting relapse in patients with residual masses after treatment. Radiography 1999;5:155–163.
   Google Scholar
• Cremerius U, Fabry U, Kroll U. Clinical value of FDG PET for therapy monitoring of malignant lymphoma – results of a retrospective study in 72 patients. Nuklearmedizin 1999;38:24–30.
   PubMedGoogle Scholar
• Jerusalem G, Beguin Y, Fassotte MF, et al Whole-body positron emission tomography using 18F-fluorodeoxyglucose compared to standard procedures for staging patients with Hodgkin's disease. Haematologica 2001;86:266–273.
   PubMed Web of Science ®Google Scholar
• Juweid ME, Wiseman GA, Vose JM, et al Response assessment of aggressive non-Hodgkin lymphoma by integrated International Workshop Criteria and fluorine-18-fluorodeoxyglucose positron emission tomography. J Clin Oncol 2005;23:4652–4661.
   PubMed Web of Science ®Google Scholar
• Naumann R, Vaic A, Beuthien-Baumann B, et al Prognostic value of positron emission tomography in the evaluation of post-treatment residual mass in patients with Hodgkin's disease and non-Hodgkin lymphoma. Br J Haematol 2001;115:793–800.
   PubMed Web of Science ®Google Scholar
• Spaepen K, Stroobants S, Dupont P, et al Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin lymphoma: is [18F]FDG-PET a valid alternative to conventional diagnostic methods? J Clin Oncol 2001;19:414–419.
   PubMed Web of Science ®Google Scholar
• Stumpe KD, Urbinelli M, Steinert HC, Glanzmann C, Buck A, von Schulthess GK. Whole-body positron emission tomography using fluorodeoxyglucose for staging of lymphoma: effectiveness and comparison with computed tomography. Eur J Nucl Med 1998;25:721–728.
   PubMedGoogle Scholar
• National Comprehensive Cancer Network. NCCN clinical practice guidelines in clinical oncology: non-Hodgkin lymphomas, ed V.3.2008. Available at http://www.nccn.org/professionals/physician_gls/f_guidelines.asp, accessed 23 November 2009.
   Google Scholar
• Juweid ME, Stroobants S, Hoekstra OS, et al Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol 2007;25:571–578.
   PubMed Web of Science ®Google Scholar
• Harris NL, Jaffe ES, Diebold J, et al World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting – Airlie House, Virginia, November 1997. J Clin Oncol 1999;17:3835–3849.
   PubMed Web of Science ®Google Scholar
• Olweny CL. Cotswolds modification of the Ann Arbor staging system for Hodgkin's disease. J Clin Oncol 1990;8:1598.
   PubMed Web of Science ®Google Scholar
• A predictive model for aggressive non-Hodgkin lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993;329:987–994.
   PubMed Web of Science ®Google Scholar
• Sachs S, Bilfinger TV. The impact of positron emission tomography on clinical decision making in a university-based multidisciplinary lung cancer practice. Chest 2005;128:698–703.
   PubMed Web of Science ®Google Scholar
• Falk MS, Truitt AK, Coakley FV, Kashani-Sabet M, Hawkins RA, Franc B. Interpretation, accuracy and management implications of FDG PET/CT in cutaneous malignant melanoma. Nucl Med Commun 2007;28:273–280.
   PubMed Web of Science ®Google Scholar
• Horning SJ, Juweid ME, Schoder H, et al Interim positron emission tomography (PET) in diffuse large B-cell lymphoma: independent expert nuclear medicine evaluation of ECOG 3404. Blood 2008;112(Suppl. 1): (page 145).
   Google Scholar
• Cashen A, Dehdashti F, Luo J, Bartlett N. Poor predictive value of FDG-PET/CT performed after 2 cycles of R-CHOP in patients with diffuse large B-cell lymphoma (DLCL). Blood 2008;112(Suppl. 1): (page 144).
   Google Scholar
• Zinzani PL, Stefoni V, Tani M, et al Role of [18F]fluorodeoxyglucose positron emission tomography scan in the follow-up of lymphoma. J Clin Oncol 2009;27:1781–1787.
   PubMed Web of Science ®Google Scholar
• Trneny M, Belohlavek O, Koren J, Pytlik R, Salkova J, Klener P. [The outcome of whole-body FDG-PET examination predicts the future of patients with diffuse large-cell lymphoma in the use of both intermediary staging and at the end of standard chemotherapy]. Vnitr Lek 2007;53:936–941.
   PubMedGoogle Scholar
• Gallamini A, Hutchings M, Rigacci L, et al Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study. J Clin Oncol 2007;25:3746–3752.
   PubMed Web of Science ®Google Scholar
• Spaepen K, Stroobants S, Dupont P, et al Early restaging positron emission tomography with (18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin lymphoma. Ann Oncol 2002;13:1356–1363.
   PubMed Web of Science ®Google Scholar
• Mikhaeel NG, Hutchings M, Fields PA, O'Doherty MJ, Timothy AR. FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma. Ann Oncol 2005;16:1514–1523.
   PubMed Web of Science ®Google Scholar
• Schot BW, Zijlstra JM, Sluiter WJ, et al Early FDG-PET assessment in combination with clinical risk scores determines prognosis in recurring lymphoma. Blood 2007;109:486–491.
   PubMed Web of Science ®Google Scholar